Nonprofit · EIN 13-3870223
INTERNATIONAL AIDS VACCINE INITIATIVE INC
Also known as DBA AIDS VACCINE INITIATIVE INTL
Tax-exempt · NEW YORK, NY 10004
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $103,360,669 | $107,326,208 | -$3,965,539 | $140,571,416 | $91,790,884 | $48,780,532 |
| December 31, 2024 | 990 | $131,181,475 | $143,043,595 | -$11,862,120 | $129,852,638 | $78,459,588 | $51,393,050 |
| December 31, 2023 | 990 | $129,678,400 | $132,896,237 | -$3,217,837 | $124,233,943 | $60,310,191 | $63,923,752 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $99,364,861
- of which government grants
- $40,186,480
- Program service revenue
- $1,240,434
- Investment income
- $2,045,077
- Net gain from sales of assets
- $142,416
- Other revenue
- $710,297
Expenses
- Grants and similar amounts paid
- $27,190,529
- Compensation of officers, directors and key employees
- $2,182,540
- Other salaries and wages
- $32,244,204
- Salaries, compensation and benefits (total)
- $43,037,681
- Professional fundraising fees
- $0
- Legal fees
- $271,027
- Accounting fees
- $296,518
- Occupancy
- $7,904,955
- Travel
- $964,607
- Depreciation
- $384,009
- Program services (functional)
- $91,410,252
- Management and general (functional)
- $15,747,759
- Fundraising (functional)
- $168,197
Balance sheet and other
- Total assets, start of year
- $129,852,638
- Total assets, end of year
- $140,571,416
- Total liabilities, end of year
- $91,790,884
- Net assets, end of year
- $48,780,532
- Land, buildings and equipment
- $456,152
- Publicly traded securities
- $31,695,203
- Net assets without donor restrictions
- $12,868,722
- Net assets with donor restrictions
- $35,911,810
- Gross receipts
- $110,643,253
- Employees
- 239
- Volunteers
- 13
- Year formed
- 1996
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO Trustee or director, Officer | 35 | $705,773 | $61,475 |
| KARA BICKHAM | CHIEF DEV. OFFICER- RESEARCH DEV. Highest-paid employee | 35 | $414,513 | $64,206 |
| SWATI GUPTA | VP, HEAD OF EID AND EPIDEMIOLOGY Highest-paid employee | 35 | $393,577 | $51,231 |
| JON HEINRICHS | VP, DISCOVERY SCIENCE Highest-paid employee | 35 | $374,045 | $57,507 |
| CHRISTOPHER PARKSASS VP | VIRAL VACC. & HEAD OF DDL Highest-paid employee | 35 | $376,537 | $51,372 |
| MARIO GAGLIANO | CHIEF PEOPLE OFFICER, VP OF HR Officer | 35 | $367,640 | $58,899 |
| MIN DING | GENERAL COUNSEL / BOARD SECRETARY Officer | 35 | $357,370 | $66,089 |
| RICHARD W WELCH | VP, BIOPROCESS DEV. & MFG. Highest-paid employee | 35 | $346,345 | $43,056 |
| BRANDON SAFT | CHIEF FINANCIAL OFFICER Officer | 35 | $331,727 | $41,476 |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER (END 3/25) Officer | 35 | $169,900 | $19,086 |
| LOUIS D SCHWARTZASST SEC | CHF.FIN. & ADMIN OFF. (END 1/25) Officer | 35 | $3,000 | $105 |
| ERIC PAUL GOOSBY MD | BOARD CHAIR Trustee or director, Officer | 2 | $0 | $0 |
| ROBERT GOLDBERG | BOARD TREASURER Trustee or director | 2 | $0 | $0 |
| LINDA- GAIL BECKER | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| DAVID BLUMBERG | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
9 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| JIM CONNOLLY | BOARD MEMBER Trustee or director | 1 | $0 |
| ALEXIS M PINTO | BOARD MEMBER Trustee or director | 1 | $0 |
| JOHN W SHIVER | BOARD MEMBER Trustee or director | 1 | $0 |
| SUSAN SILBERMANN | BOARD MEMBER Trustee or director | 1 | $0 |
| ANNE MARTIN SIMONDS | BOARD MEMBER Trustee or director | 1 | $0 |
| RAJEEV VENKAYYA | BOARD MEMBER Trustee or director | 1 | $0 |
| MARIJKE WIJNROKS | BOARD MEMBER Trustee or director | 1 | $0 |
| HON MARK DYBUL | BOARD MEMBER Trustee or director | 1 | $0 |
| WAFAA EL-SADR | BOARD MEMBER Trustee or director | 1 | $0 |
990 for the year ended December 31, 2024: 24 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO Trustee or director, Officer | 35 | $718,500 | $65,874 |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER Officer | 35 | $552,506 | $61,628 |
| SWATI GUPTA | VP, HEAD OF EID AND EPIDEMIOLOGY Highest-paid employee | 35 | $402,341 | $68,395 |
| CHRISTOPHER PARKS | ASS. VP, VIRAL VACC. & HEAD OF DDL Highest-paid employee | 35 | $380,753 | $71,334 |
| MARIO GAGLIANO | CHIEF PEOPLE OFFICER, VP OF HR Officer | 35 | $364,310 | $80,875 |
| DAGNA LAUFER | VP AND HEAD OF CLINICAL DEVELOPMENT Highest-paid employee | 35 | $402,844 | $38,942 |
| MIN DING | GENERAL COUNSEL/BOARD SECRETARY Officer | 35 | $368,570 | $72,448 |
| LOUIS D SCHWARTZ | ASST. SEC., CHIEF FIN. & ADMIN OFF. Officer | 35 | $353,545 | $68,561 |
| MARION GRUBER | VP, PUBLIC HEALTH & REG. SCIENCE Highest-paid employee | 35 | $383,236 | $38,841 |
| SANGEETHA SAGAR | VICE PRESIDENT, PDC Highest-paid employee | 35 | $384,858 | $34,985 |
| BRANDON SAFT | DEPUTY CHIEF FINANCIAL OFFICER Officer | 35 | $255,811 | $22,267 |
| ERIC PAUL GOOSBY | BOARD CHAIR Trustee or director, Officer | 2 | $0 | $0 |
| ROBERT GOLDBERG | BOARD TREASURER Trustee or director, Officer | 2 | $0 | $0 |
| LINDA-GAIL BECKER | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| DAVID BLUMBERG | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| JIM CONNOLLY | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| MARK DYBUL | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| WAFAA EL-SADR | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| ALEXIS M PINTO | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| JOHN W SHIVER | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| SUSAN SILBERMANN | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| ANNE MARTIN SIMONDS | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| RAJEEV VENKAYYA | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| MARIJKE WIJNROKS | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
990 for the year ended December 31, 2023: 24 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO Trustee or director, Officer | 35 | $719,151 | $110,715 |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER Officer | 35 | $531,087 | $79,268 |
| LOUIS D SCHWARTZ | ASST. SEC. & CFAO Officer | 35 | $390,586 | $76,520 |
| SWATI GUPTA | VP, HEAD OF EID & EPIDEM. Highest-paid employee | 35 | $379,201 | $76,490 |
| DAGNA LAUFER | VP & HEAD OF CLINICAL DEV. Highest-paid employee | 35 | $394,188 | $41,148 |
| CHRISTOPHER PARKS - ASSOC | AVP. VIRAL VAC. & HEAD OF DDL Highest-paid employee | 35 | $365,204 | $62,119 |
| SANGEETHA SAGAR | VP & HEAD OF PRODUCT DEV Highest-paid employee | 35 | $376,047 | $33,504 |
| MIN DING | GEN. COUNS. & SEC. Officer | 35 | $333,986 | $71,843 |
| ERIC SKJEVELAND | VP, BUSINESS DEVELOPMENT Highest-paid employee | 35 | $341,395 | $36,715 |
| MARIO GAGLIANO | CPO, VP OF HR (FROM 9/23) Officer | 35 | $102,045 | $14,230 |
| FRANCES SINHA | FORMER OFFICER Former | 35 | $105,000 | $0 |
| ERIC PAUL GOOSBY | BOARD CHAIR Trustee or director, Officer | 2 | $0 | $0 |
| ROBERT GOLDBERG | BOARD TREASURER Trustee or director, Officer | 2 | $0 | $0 |
| LINDA-GAIL BECKER | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| DAVID BLUMBERG | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| JIM CONNOLLY | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| MARK DYBUL | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| WAFAA EL-SADR | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| ALEXIS M PINTO | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| JOHN W SHIVER | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| SUSAN SILBERMANN | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| ANNE MARTIN SIMONDS | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| RAJEEV VENKAYYA | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| MARIJKE WIJNROKS | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 125 BROAD ST 9TH FL, NEW YORK, NY 10004-2743
- In care of
- % PATRICK MOUTON
- Principal officer (990 for 2025)
- MARK B FEINBERG, 125 BROAD STREET 9TH FL, NEW YORK, NY 10004
- Signed the 990
- BRANDON SAFT, CFO
- Phone
- (212) 847-1111
- Website
- WWW.IAVI.ORG
- Return prepared by
- GELMAN ROSENBERG & FREEDMAN
Mission
A GLOBAL NONPROFIT BIOMEDICAL RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, AND EMERGING INFECTIOUS DISEASES.
Program accomplishments
- RESEARCH AND DEVELOPMENT:THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC ( SEE SCHEDULE O FOR CONTINUATION) CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE CANDIDATE THAT HAS YIELDED PROMISING EARLY RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, AND MARBURG, SUDAN, AND BUNDIBUGYO VIRUS DISEASES, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN LOW-INCOME COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST.IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.Expenses $91,410,252 · grants $27,190,529 · revenue $1,240,434
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 13-3870223
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1996
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- International, foreign affairs and national security (Q300)
- Assets (IRS master file)
- $140,571,416
- Income (IRS master file)
- $110,643,253
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | $103,360,669 | $107,326,208 | $140,571,416 | XML |
| 990 | December 2024 | $131,181,475 | $143,043,595 | $129,852,638 | XML |
| 990 | December 2023 | $129,678,400 | $132,896,237 | $124,233,943 | XML |
| 990 | December 2022 | $146,782,280 | $131,188,762 | $128,948,484 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-3870223).
Questions about INTERNATIONAL AIDS VACCINE INITIATIVE INC
- What is the EIN of INTERNATIONAL AIDS VACCINE INITIATIVE INC?
- The employer identification number (EIN) of INTERNATIONAL AIDS VACCINE INITIATIVE INC is 13-3870223.
- Is INTERNATIONAL AIDS VACCINE INITIATIVE INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1996.
- Are donations to INTERNATIONAL AIDS VACCINE INITIATIVE INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does INTERNATIONAL AIDS VACCINE INITIATIVE INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of INTERNATIONAL AIDS VACCINE INITIATIVE INC due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did INTERNATIONAL AIDS VACCINE INITIATIVE INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of INTERNATIONAL AIDS VACCINE INITIATIVE INC?
- The 990 for the year ended December 31, 2025 names MARK B FEINBERG.
- Who are the officers and directors of INTERNATIONAL AIDS VACCINE INITIATIVE INC?
- The 990 for the year ended December 31, 2025 lists 24 people; 11 received compensation from the organization, the highest $705,773 (MARK B FEINBERG, PRESIDENT/CEO).
- How much revenue does INTERNATIONAL AIDS VACCINE INITIATIVE INC have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $103,360,669, expenses of $107,326,208 and total assets of $140,571,416 at year end.
Other nonprofits in NEW YORK
- INTERNATIONAL RESCUE COMMITTEE INC EIN 13-5660870 · last filed 990 for 2025
- UNITED STATES FUND FOR UNICEF EIN 13-1760110 · last filed 990 for 2025
- PLAN INTERNATIONAL INC EIN 51-0169168 · last filed 990 for 2025
- MEDECINS SANS FRONTIERES USA INC EIN 13-3433452 · last filed 990 for 2024
- WORLD ECONOMIC FORUM EIN 98-0459408 · last filed 990 for 2025
- AMERICAN JEWISH JOINT DISTRIBUTION COMMITTEE INC EIN 13-1656634 · last filed 990 for 2024
- UNITED ISRAEL APPEAL INC EIN 13-1760102 · last filed 990 for 2025
- CATHOLIC MEDICAL MISSION BOARD INC EIN 13-5602319 · last filed 990 for 2025
All nonprofits in NEW YORK · New York · International, foreign affairs and national security